Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 4/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932337 | 0.81 | JAK3 (0.41) | LIPE | |
| SCHEMBL24755151 | 0.81 | HDAC3 (0.33) | LIPE | |
| SCHEMBL22931775 | 0.80 | RXRA (0.32) | XDHRXRANR1H2NR1H3LIPE | |
| SCHEMBL29420832 | 0.80 | RXRA (0.32) | XDHRXRANR1H2NR1H3LIPE | |
| SCHEMBL29806156 | 0.80 | LIPE (0.37) | RXRANR1H2NR1H3LIPEMT-CO2 | |
| SCHEMBL22931772 | 0.80 | LIPE (0.37) | RXRANR1H2NR1H3LIPEMT-CO2 | |
| SCHEMBL22932338 | 0.77 | CNR1 (0.32) | CACNA1GCACNA1BCACNA1C | |
| SCHEMBL22931787 | 0.76 | MT-CO2 (0.37) | RXRANR1H2NR1H3LIPEMT-CO2 | |
| SCHEMBL22931811 | 0.74 | MT-CO2 (0.35) | RXRANR1H2NR1H3LIPEMT-CO2 | |
| SCHEMBL22932340 | 0.74 | SYK (0.46) | MT-CO2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARM INT AG (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2021018869-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | OXER1, CBR3, CCNY | XDH 1039/4885RXRA 883/4885NR1H2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.